<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Hanmi Pharma on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/hanmi-pharma/</link><description>Recent content in Hanmi Pharma on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Fri, 06 Nov 2026 23:40:02 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/hanmi-pharma/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch 2026-11-06: HMM, Hanmi Pharm &amp; Dongkook Lead</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</link><pubDate>Fri, 06 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Change&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,060&lt;/td&gt;
 &lt;td&gt;−13.6%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;644&lt;/td&gt;
 &lt;td&gt;−12.3%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,356&lt;/td&gt;
 &lt;td&gt;+2.3%&lt;/td&gt;
 &lt;td&gt;KRW weak&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;26.8&lt;/td&gt;
 &lt;td&gt;+26.6%&lt;/td&gt;
 &lt;td&gt;Caution&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$98.4&lt;/td&gt;
 &lt;td&gt;−6.1%&lt;/td&gt;
 &lt;td&gt;Falling&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.84%&lt;/td&gt;
 &lt;td&gt;−0.09pp&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Korea regime: Bear. US regime: Neutral&lt;/strong&gt; — the US just downgraded from Bull this run. Only 14.5% of Korean stocks trade above their 50-day moving average; 12.8% above the 200-day. KOSPI sits at 5,060 against a 200DMA of 6,511. KRX program selling hit −₩1.61 trillion on the session, basis −0.28.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Market Snapshot, 2026-11-06. No same-day close briefing was available; a stale prior briefing was intentionally blocked.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s session was a broad, largely indiscriminate selloff. Of 2,595 stocks tracked, 2,035 declined and only 335 advanced — an advance-decline ratio of roughly 1:6. The average stock fell 2.34%. Program selling (−₩1.61 trillion net, nearly all non-arbitrage) confirmed systematic de-risking rather than targeted rotation. ETF net creation was a modest +₩181 billion — passive inflows providing a marginal cushion against the tide.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Batteries and semiconductors led the decline.&lt;/strong&gt; Samsung SDI (006400.KS, −8.06%), LG Chem (051910.KS, −5.69%), EcoPro (086520.KS, −6.89%), and L&amp;amp;F (066970.KQ, −12.60%) all fell sharply, with institutions actively selling SDI and L&amp;amp;F. On the semiconductor side, TES (095610.KS, −11.59%), Dooson Tesna (131970.KS, −10.85%), FADU (440110.KQ, −10.27%), and TCK (064760.KQ, −11.41%) were battered. Korea Finance Holdings (071050.KS, −17.34%) stood out as the worst single-name move, with heavy institutional selling.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Internet and IT services were the clearest defensive pocket.&lt;/strong&gt; NAVER (035420.KS, +2.87%) was the only large-cap that attracted both foreign and institutional buying simultaneously. Samsung SDS (018260.KS, +6.34%) also drew institutional flows. Samsung Biologics (207940.KS, −0.26%) was nearly flat — the healthiest of the defensives among large caps.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Foreign flow diverged from price.&lt;/strong&gt; Foreigners sold financials outright: KB Financial (105560.KS, −3.82%), Woori Financial (316140.KS, −1.72%), and Shinhan (055550.KS, −2.25%) all saw foreign outflows. Samsung C&amp;amp;T (028260.KS, −5.85%) and Samsung SDI were also on the foreign sell list. On the other side, foreigners bought POSCO Holdings (005490.KS, −3.11%) and TES despite price declines — a potential signal for recovery scenarios.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Institutions bought financials that foreigners sold.&lt;/strong&gt; KB Financial, Woori, Shinhan, and Hyundai Motor (005380.KS) all appeared on institutional buy lists. The setup — foreign selling, domestic institutional absorbing — may reflect a rotation toward domestic yield plays as Korean 10-year bonds fell to 3.887%, a five-week low. Korean AA− corporate spreads over 3-year KTBs tightened to 0.69pp, one of the more stable readings in the current drawdown.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Meta Screener, 2026-11-06. The PEAD-only screener intersection shows no 2+ overlaps today on that dimension; multi-signal analysis draws on the full meta screener combining 8 screener families across 104 tickers.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s meta screener calibrates weights on 95 days of live forward returns. The dominant signal is &lt;strong&gt;consensus revision (2.18× weight, +1.76pp vs. pool average over 97 sample days)&lt;/strong&gt;. RS80 leadership (1.31×) and quiet accumulation (1.00×) follow. The financial-quality factor cluster — Quality Compounder, Smart Money Quality, Cycle Rerating, Smart Money Earnings — carries 0.60× per family, meaningful when stacked but not dominant alone.&lt;/p&gt;
&lt;h3 id="top-candidates--2026-11-06"&gt;Top Candidates — 2026-11-06
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th&gt;Meta Score&lt;/th&gt;
 &lt;th&gt;Screener Families&lt;/th&gt;
 &lt;th&gt;Evidence Pts&lt;/th&gt;
 &lt;th&gt;Key Metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;1&lt;/td&gt;
 &lt;td&gt;011200.KS&lt;/td&gt;
 &lt;td&gt;HMM&lt;/td&gt;
 &lt;td&gt;34.2&lt;/td&gt;
 &lt;td&gt;Consensus Up, Quiet Accum., RS80&lt;/td&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;Consensus z +0.52; retail −₩21.96B; RS80 pivot gap +10.5%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharm&lt;/td&gt;
 &lt;td&gt;54.7&lt;/td&gt;
 &lt;td&gt;Consensus Up, Cycle, SM Quality, SM Earnings&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;Margin +2.2pp; F+QI net +₩73.3B 5-day; DART catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharma&lt;/td&gt;
 &lt;td&gt;68.1&lt;/td&gt;
 &lt;td&gt;Quality, Cycle, PEAD, Quiet Accum.&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;ROE 9.9%; OP YoY +20.1%; margin +0.5pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td&gt;23.3&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +5.78; IR event catalyst; retail −₩10.65B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;071970.KS&lt;/td&gt;
 &lt;td&gt;HD Hyundai Marine Engine&lt;/td&gt;
 &lt;td&gt;20.5&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +0.51; Q3 prelim + supply contract filed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;6&lt;/td&gt;
 &lt;td&gt;079160.KS&lt;/td&gt;
 &lt;td&gt;CJ CGV&lt;/td&gt;
 &lt;td&gt;19.1&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +0.83; Q3 prelim filed today&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;7&lt;/td&gt;
 &lt;td&gt;383800.KS&lt;/td&gt;
 &lt;td&gt;LX Holdings&lt;/td&gt;
 &lt;td&gt;17.0&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +3.88; Q3 prelim filed Nov 4&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;#1 — HMM (011200.KS): Three Independent Signals, No DART Risk Flags&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;HMM is Korea&amp;rsquo;s largest container shipping line. It ranks first because it combines three independently weighted signal families: rising analyst consensus (z +0.52), quiet accumulation by foreigners and quality institutions while retail sold −₩21.96 billion, and RS80 leadership that cleared the late-stage filter (20-day flow/volume momentum +21.6%, box risk −14.7%). No filings appeared in the DART lookback window — the absence of risk disclosures is a clean read in the current environment. The RS80 weight (1.31×) stacked on consensus (2.18×) explains the top meta rank despite fewer quality-factor signals than the names below it. What to check next: spot freight rate trends and Q3 earnings timing.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#2 — Hanmi Pharm (128940.KS): DART Catalyst + Four Screeners + Smart Money vs. Retail Divergence&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hanmi Pharmaceutical is one of Korea&amp;rsquo;s leading biopharmaceutical companies, known for GLP-1, oncology, and rare disease pipelines. It hits four screener families: Cycle Rerating (operating margin expanded +2.2pp), Smart Money Quality (foreigners and quality institutions absorbed a net +₩73.3 billion over five days while retail sold −₩58.83 billion), Smart Money Earnings, and consensus revision. The DART overlay adds confirmed catalysts: a Fabry disease drug (LAGLA) licensing deal filed Oct 30, plus two IR events in late October and early November. The divergence between retail outflows and institutional/foreign inflows is the sharpest flow split in today&amp;rsquo;s candidate pool. What to check next: LAGLA deal geography and upfront payment structure; whether the IR calendar signals Q3 results disclosure.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#3 — Dongkook Pharma (086450.KS): Quality Compounder + Cycle + PEAD — Operational Leverage Stacking&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkook Pharmaceutical is a mid-cap consumer health and prescription drug company with a branded OTC portfolio alongside ethical pharmaceuticals. It clears four screener families: Quality Compounder (ROE 9.9%, OP YoY +20.1%), Cycle Rerating (margin +0.5pp), PEAD (OP YoY 20%, revenue +14.1%, 52-week gap remaining 21.2%), and quiet accumulation (retail −₩6.85 billion absorbed by foreigners and quality institutions). The raw meta score of 68.1 is the highest in today&amp;rsquo;s pool. It also appears independently in the PEAD Tier C list. The core story is operational leverage: revenue growth converting into margin expansion and beginning to attract institutional re-pricing. What to check next: OTC vs. prescription revenue mix and whether the OP growth rate is sustainable at the current sales base.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;All data sourced from Research OS internal DB as of 2026-11-06. Candidates are screener outputs for research prioritization, not buy or sell recommendations. PEAD sub-index intersection: no 2+ overlaps on that dimension today.&lt;/em&gt;&lt;/p&gt;</description></item><item><title>Korea Quality Re-Rating Watch 2026-11-05: Dongkook, Hanmi &amp; HMM</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-05/</link><pubDate>Thu, 05 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-05/</guid><description>&lt;h2 id="macro-dashboard--2026-11-05"&gt;Macro Dashboard — 2026-11-05
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Δ&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,383.8&lt;/td&gt;
 &lt;td&gt;−6.1%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;678.4&lt;/td&gt;
 &lt;td&gt;−6.4%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;16.82&lt;/td&gt;
 &lt;td&gt;−2.2%&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.89%&lt;/td&gt;
 &lt;td&gt;−0.09pp&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,342.8&lt;/td&gt;
 &lt;td&gt;+0.4%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$96.2&lt;/td&gt;
 &lt;td&gt;−8.2%&lt;/td&gt;
 &lt;td&gt;Falling&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;DXY&lt;/td&gt;
 &lt;td&gt;101.5&lt;/td&gt;
 &lt;td&gt;−0.7%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Regime: KR Bear | US Bull&lt;/strong&gt; (11/12 inputs verified). Only 16.7% of Korean stocks trade above their 50-day moving average; 40.3% of US stocks do. VIX at 16.8 and US yields drifting lower confirm this is a Korea-specific drawdown, not a global risk-off event.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;Korea&amp;rsquo;s November 5 session was a broad, technically-driven sell-off with two distinct pockets of institutional support cutting against the tide.&lt;/p&gt;
&lt;p&gt;The aggregate picture leaves little room for interpretation: 1,714 stocks fell, 635 rose, and the average stock declined 1.96%. Program selling totaled ₩1.69 trillion net while ETF redemptions reached ₩1.52 trillion. Futures basis sat at −0.53. This is systematic passive de-risking — not a single-sector event.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Where money entered.&lt;/strong&gt; Internet and platform names were the session&amp;rsquo;s standout. NAVER (035420.KS, +8.26%) attracted simultaneous foreign and institutional net buying — a rare alignment on a down day. Kakao (035720.KS, +10.65%) drew the heaviest foreign inflows of any name. Hybe (352820.KS, +8.19%) also saw foreign accumulation. The likely driver: falling oil prices and stabilizing US yields created a rotation window into domestic internet names that had lagged through October.&lt;/p&gt;
&lt;p&gt;Financials were the second destination for institutional flows. KB Financial (105560.KS, +3.63%), Woori Financial (316140.KS, +5.27%), Hyundai Mobis (012330.KS, +2.54%), Hyundai Motor (005380.KS, +3.53%), and Hana Financial (086790.KS, +3.16%) all recorded institutional net buying. Samsung Biologics (207940.KS, +1.67%) was bought by institutions even as foreign investors trimmed. Koryo Zinc (010130.KS, +11.0%) surged with institutional support; foreign investors were on the other side.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Where money exited.&lt;/strong&gt; Semiconductors and the battery supply chain bore the heaviest institutional selling. PSK Holdings (031980.KS, −19.4%), Lotte Energy Materials (020150.KS, −18.4%), Doosan (000150.KS, −17.5%), TES (095610.KS, −17.1%), and Doosan Tesna (131970.KS, −16.1%) all saw combined foreign and institutional selling. Samsung SDI (006400.KS, −6.6%) and S-Oil (010950.KS, −6.2%) declined as institutions distributed. The common thread across the losers: capex-intensive businesses where slowing order visibility or margin pressure makes the near-term earnings trajectory harder to defend.&lt;/p&gt;
&lt;p&gt;The split is clean. Quality internet and financial franchises absorbed institutional flows; semis, batteries, and energy supply chain were the exits. With KOSPI and KOSDAQ both trading more than 20% below their 200-day moving averages, the structural backdrop remains broken. But within that environment, some businesses are being selectively re-priced higher.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Note: Same-day full close briefing unavailable; this section is sourced from the same-day Research OS market snapshot.&lt;/em&gt;&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;The KR Meta Screener evaluated 109 tickers and ranked 20 article candidates for November 5. The PEAD screener produced no 2+ overlap candidates on its own today. The meta screener&amp;rsquo;s multi-family scoring identifies the stronger setups, where quality fundamentals, money flow, and an earnings or cycle catalyst converge.&lt;/p&gt;
&lt;h3 id="top-candidates-meta-screener-rank"&gt;Top Candidates (Meta Screener Rank)
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Meta Score&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Families&lt;/th&gt;
 &lt;th&gt;Screeners Hit&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;76.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD, Quiet Accumulation, RS80&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharma&lt;/td&gt;
 &lt;td style="text-align: right"&gt;53.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (5 evidence)&lt;/td&gt;
 &lt;td&gt;Smart Money Quality, Cycle Rerating, Consensus Up, Smart Money Earnings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;011200.KS&lt;/td&gt;
 &lt;td&gt;HMM&lt;/td&gt;
 &lt;td style="text-align: right"&gt;36.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus Up, Quiet Accumulation, RS80&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;089860.KS&lt;/td&gt;
 &lt;td&gt;Lotte Rental&lt;/td&gt;
 &lt;td style="text-align: right"&gt;35.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Cycle Rerating, Quiet Accumulation, RS80 + same-day DART prelim&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;036460.KS&lt;/td&gt;
 &lt;td&gt;KOGAS&lt;/td&gt;
 &lt;td style="text-align: right"&gt;30.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (5 evidence)&lt;/td&gt;
 &lt;td&gt;Quiet Accumulation, RS80, Kiwoom surface + buyback DART&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;030000.KS&lt;/td&gt;
 &lt;td&gt;Cheil Worldwide&lt;/td&gt;
 &lt;td style="text-align: right"&gt;29.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (4 evidence)&lt;/td&gt;
 &lt;td&gt;Quiet Accumulation, RS80 + same-day DART prelim&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;071970.KS&lt;/td&gt;
 &lt;td&gt;HD Hyundai Marine Engine&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (4 evidence)&lt;/td&gt;
 &lt;td&gt;Consensus Up, Kiwoom surface + 3 DART catalysts&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;22.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1 (3 evidence)&lt;/td&gt;
 &lt;td&gt;Consensus Up (z +5.88), IR event DART&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;#1 — Dongkook Pharmaceutical (086450.KS, Score 76.7)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkook is a mid-cap Korean pharma spanning OTC topical drugs, prescription products, and health supplements. It leads today&amp;rsquo;s candidates because it registers across the most independent screener families: Quality Compounder (ROE 9.9%, operating profit YoY +20.1%), Cycle Rerating (margin expansion +0.5pp), Quiet Accumulation (foreign ownership rising in a compressed price range, retail selling ₩7.6bn absorbed by institutional and foreign buyers), RS80 not-late leadership (MA50 premium +10.5%, 20-day flow momentum +22%), and Tier C of the PEAD screener (OP growth +20%, margin +0.52pp). The convergence of quality fundamentals and quiet buying pressure in a down market is the signal. Key caveat: the PEAD financial data is based on FY2025Q4 (filing age 238 days). The next verification is a fresh 1H2026 earnings release that either confirms or cancels the margin expansion story.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#2 — Hanmi Pharma (128940.KS, Score 53.8)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hanmi is one of Korea&amp;rsquo;s most active drug-licensing platforms, with a deepening pipeline in obesity and rare diseases. Today it hits Smart Money Quality (net foreign + institutional buying of ₩60.3bn over five days), Cycle Rerating (margin expansion +2.2pp — the strongest margin signal among all candidates today), Consensus Up Revision, and Smart Money Earnings. Retail sold ₩55bn; institutional and foreign absorbed. A live DART catalyst reinforces the picture: an October 30 technology-transfer agreement for the Fabry disease treatment LAGLA. The core question for follow-up research is whether the consensus revision is driven by this single licensing event — making it one-time — or by underlying pipeline momentum that sustains the margin improvement into 2H2026.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#3 — HMM (011200.KS, Score 36.8)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;HMM is Korea&amp;rsquo;s largest container shipping company. It qualifies via Consensus Up Revision (composite z-score +0.53), Quiet Accumulation (foreign ownership rising in a narrow price range, retail selling ₩34.6bn absorbed by institutional and foreign flows), and RS80 Not-Late Leadership (pivot gap +6.9%, Focus Candidate classification, 20-day supply-demand momentum +22.5%). A DART disclosure filed October 15 shows new facility investment, potentially signaling fleet expansion plans. With Brent crude falling 8.2% over five days, shipping input costs are easing — a potential margin tailwind that may explain the consensus upgrade. The critical next check is whether spot shipping rates (BDI, CCFI) are recovering to validate the earnings revision, or whether the upgrade is running ahead of fundamentals.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;Source: Research OS macro-regime data (11/12 inputs current), same-day KR market snapshot, and KR Meta Screener as of 2026-11-05. This post is market analysis and does not constitute investment advice.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>